J. P. Bizzari

455 total citations
10 papers, 340 citations indexed

About

J. P. Bizzari is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, J. P. Bizzari has authored 10 papers receiving a total of 340 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Molecular Biology, 5 papers in Oncology and 4 papers in Pulmonary and Respiratory Medicine. Recurrent topics in J. P. Bizzari's work include Cancer Treatment and Pharmacology (3 papers), Lung Cancer Treatments and Mutations (3 papers) and Cancer therapeutics and mechanisms (2 papers). J. P. Bizzari is often cited by papers focused on Cancer Treatment and Pharmacology (3 papers), Lung Cancer Treatments and Mutations (3 papers) and Cancer therapeutics and mechanisms (2 papers). J. P. Bizzari collaborates with scholars based in France, United Kingdom and Switzerland. J. P. Bizzari's co-authors include D. Khayat, Pierre Banzet, C Jacquillat, M. Namer, Pierre Kerbrat, Jacques Bonneterre, J. J. Bonerandi, R. Bugat, C Vilmer and R Lauvin and has published in prestigious journals such as Cancer, British Journal of Cancer and Annals of Oncology.

In The Last Decade

J. P. Bizzari

10 papers receiving 334 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
J. P. Bizzari France 8 227 173 117 60 48 10 340
Darab Kamanabrou Germany 6 372 1.6× 305 1.8× 81 0.7× 29 0.5× 139 2.9× 7 517
Laura Kirby Australia 8 245 1.1× 169 1.0× 128 1.1× 30 0.5× 36 0.8× 11 362
Benedetta Pellegrino Italy 11 205 0.9× 95 0.5× 124 1.1× 25 0.4× 54 1.1× 34 351
L. Hart United States 11 254 1.1× 220 1.3× 183 1.6× 43 0.7× 13 0.3× 25 518
Leticia Tetteh United States 6 306 1.3× 197 1.1× 112 1.0× 36 0.6× 149 3.1× 11 456
Vanessa Salazar United States 8 561 2.5× 149 0.9× 169 1.4× 121 2.0× 15 0.3× 16 654
J. Infante United States 8 137 0.6× 156 0.9× 66 0.6× 15 0.3× 30 0.6× 17 273
Bharani Dharan United States 6 144 0.6× 152 0.9× 120 1.0× 38 0.6× 24 0.5× 10 324
Chaitanya Iragavarapu United States 8 138 0.6× 213 1.2× 71 0.6× 66 1.1× 51 1.1× 15 392
Margit Stimpfl Austria 11 105 0.5× 193 1.1× 32 0.3× 29 0.5× 59 1.2× 16 372

Countries citing papers authored by J. P. Bizzari

Since Specialization
Citations

This map shows the geographic impact of J. P. Bizzari's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. P. Bizzari with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. P. Bizzari more than expected).

Fields of papers citing papers by J. P. Bizzari

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. P. Bizzari. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. P. Bizzari. The network helps show where J. P. Bizzari may publish in the future.

Co-authorship network of co-authors of J. P. Bizzari

This figure shows the co-authorship network connecting the top 25 collaborators of J. P. Bizzari. A scholar is included among the top collaborators of J. P. Bizzari based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J. P. Bizzari. J. P. Bizzari is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

10 of 10 papers shown
1.
2.
O’Brien, Michelle, Robert Leonard, Peter Barrett‐Lee, S. Peter Eggleton, & J. P. Bizzari. (1999). Docetaxel in the community setting: An analysis of 377 breast cancer patients treated with docetaxel (Taxotere®) in the UK. Annals of Oncology. 10(2). 205–210. 37 indexed citations
3.
Chevalier, Thierry Le, J. Bérille, John Zalcberg, et al.. (1999). Overview of docetaxel (Taxotere)/cisplatin combination in non-small cell lung cancer.. PubMed. 26(3 Suppl 11). 13–8. 12 indexed citations
4.
Rixe, Olivier, Christian Borel, D. Paraïso, et al.. (1995). Fotemustine, dacarbazine, vindesine combination chemotherapy in advanced malignant melanoma. Melanoma Research. 5(6). 419–424. 10 indexed citations
5.
Pujol, Jean-Louis, Alain Monnier, J. Bérille, et al.. (1994). Phase II study of nitrosourea fotemustine as single-drug chemotherapy in poor-prognosis non-small-cell lung cancer. British Journal of Cancer. 69(6). 1136–1140. 21 indexed citations
6.
Fischel, Jean–Louis, et al.. (1994). [Tamoxifen increases cytotoxic effects of fotemustine. Experimental results on cell lines of human melanoma].. PubMed. 81(7). 599–604. 3 indexed citations
7.
Gérard, B., Steinar Aamdal, Serge Leyvraz, et al.. (1993). Activity and unexpected lung toxicity of the sequential administration of two alkylating agents—Dacarbazine and fotemustine—in patients with melanoma. European Journal of Cancer. 29(5). 711–719. 41 indexed citations
8.
Khayat, D., et al.. (1992). Fotemustine. Melanoma Research. 2(3). 147–152. 15 indexed citations
9.
Fischel, Jean–Louis, Patricia Formento, M C Etienne, et al.. (1990). In vitro chemosensitivity testing of Fotemustine (S 10036), a new antitumor nitrosourea. Cancer Chemotherapy and Pharmacology. 25(5). 337–341. 25 indexed citations
10.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Darab Kamanabrou Breakdown of academic impact, for papers by Laura Kirby Breakdown of academic impact, for papers by Benedetta Pellegrino Breakdown of academic impact, for papers by L. Hart Breakdown of academic impact, for papers by Leticia Tetteh Breakdown of academic impact, for papers by Vanessa Salazar Breakdown of academic impact, for papers by J. Infante Breakdown of academic impact, for papers by Bharani Dharan Breakdown of academic impact, for papers by Chaitanya Iragavarapu Breakdown of academic impact, for papers by Margit Stimpfl
Rankless by CCL
2026